Eli Lilly and Company has significantly deepened its footprint in cutting-edge drug discovery by expanding its strategic partnership and licensing…
Read More
Shionogi Expands Rare Disease Portfolio With $2 Billion Acquisition of IntraBio and Flagship Drug Aqneursa
Japanese pharmaceutical major Shionogi has announced a definitive agreement to acquire IntraBio in a multibillion-dollar transaction valued at $2 billion.…
Read More
Bayer Commits $2.2bn to Establish State-of-the-Art Pharmaceutical Manufacturing Facility at New Albany International Business Park in Ohio
Life sciences giant Bayer has announced a monumental $2.2bn capital investment dedicated to the construction of a cutting-edge pharmaceutical manufacturing…
Read More
FDA approves expanded indication for Lilly’s Jaypirca
The United States Food and Drug Administration (FDA) has granted an expanded regulatory approval for Eli Lilly and Company’s Jaypirca,…
Read More
Pioneering Optogenetics Research Earns 2026 Nobel Prize in Physiology or Medicine and Ushers in a New Frontier for Ophthalmology
The 2026 Nobel Prize in Physiology or Medicine has been awarded to a distinguished trio of researchers—Karl Deisseroth of Stanford…
Read More
Navigating the Challenge of GLP-1RA Non-Responders in Obesity and Metabolic Disease Management
The rapid global adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs) has fundamentally transformed the therapeutic landscape for obesity and type…
Read More
EASD 2026: Tirzepatide Outperforms Semaglutide in Real-World Type 2 Diabetes Analysis
The landscape of metabolic disease management continues to undergo a profound transformation as comparative clinical data accumulates for the newest…
Read More
BioMarin Pharmaceutical and Profluent Partner to Accelerate AI-Driven Enzyme Therapies in Landmark Drug Discovery Collaboration
In a significant move bridging artificial intelligence and biotechnology, BioMarin Pharmaceutical has forged a strategic research collaboration with Emeryville-based tech…
Read More
FDA Expands Approval of Bristol Myers Squibb’s Camzyos to Treat Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy
The United States Food and Drug Administration (FDA) has officially expanded the approved indication for Bristol Myers Squibb’s (BMS) flagship…
Read More
Varda Space Industries Secures $251m in Series D Funding to Pioneer Commercial In-Space Pharmaceutical Manufacturing
Varda Space Industries has successfully closed a massive $251m Series D financing round, bringing its cumulative venture backing to $598m…
Read More
